ropsacitinib
TYK2 inhibitor
Also Known As:
3-(cyanomethyl)-3-(4-(6-(1-methylpyrazol-4-yl)pyrazolo(1,5-a)pyrazin-4-yl)pyrazol-1-yl)cyclobutane-1-carbonitrile; PF-06826647
Networked: 4
relevant articles (1 outcomes,
2 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
| 1. | Blauvelt, Andrew:
1 article
(01/2022)
|
| 2. | Gale, Jeremy D:
1 article
(01/2022)
|
| 3. | Krueger, James G:
1 article
(01/2022)
|
| 4. | McInnes, Iain B:
1 article
(01/2022)
|
| 5. | Peeva, Elena:
1 article
(01/2022)
|
| 6. | Pradhan, Vivek:
1 article
(01/2022)
|
| 7. | Roberts, Erika S:
1 article
(01/2022)
|
| 8. | Singh, Ravi Shankar P:
1 article
(01/2022)
|
| 9. | Tarabar, Sanela:
1 article
(01/2022)
|
| 10. | Tehlirian, Christopher:
1 article
(01/2022)
|
Related Diseases
| 1. | Psoriasis (Pustulosis Palmaris et Plantaris)
01/01/2023
- " Furthermore, phase II clinical trials for ropsacitinib (PF-06826647), a selective TYK2 inhibitor, and brepocitinib (PF-06700841), a JAK1/TYK2 inhibitor, have also demonstrated efficacy and an acceptable safety profile in adult patients with moderate-to-severe plaque psoriasis. " 03/01/2020
- " Further, the selective TYK2 inhibitor PF-06826647 is being tested in moderate-to-severe psoriasis in a Phase II clinical trial. " 01/01/2022
- " Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study." 01/01/2022
- " To evaluate the efficacy and safety of tyrosine kinase 2 inhibitor, PF-06826647, in moderate-to-severe plaque psoriasis. " 01/01/2022
- " Deucravacitinib, which is an oral, selective inhibitor that binds to the regulatory domain of TYK2, and brepocitinib (PF-06700841) and PF-06826647, which are topical and oral TYK2 inhibitors, respectively, that bind to the active (adenosine triphosphate-binding) site in the catalytic domain, are in development for psoriasis. "
|
|
Related Drugs and Biologics